Impact of 13-valent pneumococcal conjugate vaccine (PCV13) in a pandemic similar to the 2009 H1N1 in the United States

BMC Infectious Diseases

Milton CWeinstein⁴  David RStrutton³  Keith PKlugman¹  Jaime LRubin²  Kristen EGilmore²  Lisa JMcGarry² 

[1] Department of Global Health, Rollins School of Public Health, Emory University, 1518 Clifton Road, N.E - Room 720, Atlanta, GA, 30322, USA;OptumInsight, One Main Street, Suite 1040, Cambridge, MA, 02142, USA;Pfizer, 500 Arcola Road, Collegeville, PA, 19426, USA;Center for Health Decision Science, Harvard School of Public Health, Harvard University, 718 Huntington Avenue, Boston, MA, 02115, USA

关键词: H1N1 pandemic;    Influenza;    Pneumococcal disease;   

Others  :  1148304
DOI  :  10.1186/1471-2334-13-229

 received in 2012-08-07, accepted in 2013-04-23,  发布年份 2013

【 摘 要 】

Background

High rates of bacterial coinfection in autopsy data from the 2009 H1N1 influenza (“flu”) pandemic suggest synergies between flu and pneumococcal disease (PD) during pandemic conditions, and highlight the importance of interventions like the 13-valent pneumococcal conjugate vaccine (PCV13) that may mitigate the impact of a pandemic.

Methods

We used a decision-analytic model, estimated from published sources, to assess the impact of pediatric vaccination with PCV13 versus the 7-valent vaccine (PCV7) on PD incidence and mortality in a normal flu season (10% flu incidence) and in a pandemic similar to 2009-2010 H1N1 (20% flu incidence, mild virulence, high impact in children). Both direct and indirect (herd) effects against PD were considered. Effectiveness of PCV13 was extrapolated from observed PCV7 data, using assumptions of serotype prevalence and PCV13 protection against the 6 serotypes not in PCV7. To simulate 2009–2010 H1N1, autopsy data were used to estimate the overall proportion of flu deaths with bacterial coinfections. By assuming that increased risk of death during the pandemic occurred among those with comorbidity (using obesity as proxy) and bacterial coinfections primarily due to S. pneumoniae or S. aureus, we estimated the proportion co-infected among all (fatal and non-fatal) flu cases (7.6% co-infected with any organism; 2.2% with S. pneumoniae). PD incidence, mortality, and total healthcare costs were evaluated over a 1-year horizon.

Results

In a normal flu season, compared to PCV7, PCV13 is expected to prevent an additional 13,400 invasive PD (IPD) cases, 399,000 pneumonia cases, and 2,900 deaths, leading to cost savings of $472 M. In a pandemic similar to 2009–2010 H1N1, PCV13 would prevent 22,800 IPD cases, 872,000 pneumonia cases, and 3,700 deaths, resulting in cost savings of $1.0 B compared to PCV7.

Conclusions

In a flu pandemic similar to the 2009–2010 H1N1, protection against the 6 additional serotypes in PCV13 would likely be effective in preventing pandemic-related PD cases, mortality, and associated costs.

【 授权许可】

   
2013 McGarry et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Kamps BS, Hoffmann C, Preiser W: Influenza report 2006. http://www.influenzareport.com webcite Accessed December 24, 2008
• [2]Trust for America’s Health: Pandemic flu and the potential for U.S. economic recession: a state-by-state analysis, March 2007. http://healthyamericans.org/reports/flurecession/ webcite Accessed December 24, 2008
• [3]Taubenberger JK, Morens DM: 1918 Influenza: the mother of all pandemics. http://www.cdc.gov/ncidod/EID/vol12no01/05-0979.htm webcite Accessed December 24, 2008
• [4]Johnson NP, Mueller J: Updating the accounts: global mortality of the 1918–1920 “Spanish” influenza pandemic. Bull Hist Med 2002, 76(1):105-115.
• [5]Muir R, Haswell Wilson G: Observations on influenza and its complications. Br Med J 1919, 1(3027):3-5.
• [6]Morens DM, Taubenberger JK, Fauci AS: Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis 2008, 198(7):962-970.
• [7]Sheng ZM, Chertow DS, Ambroggio X, McCall S, Przygodzki RM, Cunningham RE, Maximova OA, Kash JC, Morens DM, Taubenberger JK: Autopsy series of 68 cases dying before and during the 1918 influenza pandemic peak. Proc Natl Acad Sci USA 2011, 108(39):16416-16421.
• [8]Chan M: World now at the start of 2009 influenza pandemic. Statement to the press by the World Health Organization. 2009. http://www.who.int/mediacentre/news/statements/2009/h1n1_pandemic_phase6_20090611/en/ webcite Accessed April 1, 2010
• [9]World Health Organization: Pandemic (H1N1) 2009 – update 74. http://www.who.int/csr/don/2009_11_13/en/index.html webcite Accessed November 18, 2012
• [10]Dhanoa A, Fang NC, Hassan SS, Kaniappan P, Rajasekaram G: Epidemiology and clinical characteristics of hospitalized patients with pandemic influenza A (H1N1) 2009 infections: the effects of bacterial coinfection. Virol J 2011, 8:501. BioMed Central Full Text
• [11]Palacios G, Hornig M, Cisterna D, Savji N, Bussetti AV, Kapoor V, Hui J, Tokarz R, Briese T, Baumeister E, Lipkin WI: Streptococcus pneumoniae coinfection is correlated with the severity of H1N1 pandemic influenza. PLoS One 2009, 4(12):e8540.
• [12]Mauad T, Hajjar LA, Callegari GD, da Silva LF, Schout D, Galas FR, Alves VA, Malheiros DM, Auler JO Jr, Ferreira AF, Borsato MR, Bezerra SM, Gutierrez PS, Caldini ET, Pasqualucci CA, Dolhnikoff M, Saldiva PH: Lung pathology in fatal novel human influenza a (H1N1) infection. Am J Respir Crit Care Med 2010, 181:72-79.
• [13]Gill JR, Sheng ZM, Ely SF, Guinee DG, Beasley MB, Suh J, Deshpande C, Mollura DJ, Morens DM, Bray M, Travis WD, Taubenberger JK: Pulmonary pathologic findings of fatal 2009 pandemic influenza a/H1N1 viral infections. Arch Pathol Lab Med 2010, 134:235-243.
• [14]Centers for Disease Control and Prevention: Bacterial coinfections in lung tissue specimens from fatal cases of 2009 pandemic influenza a (H1N1) – united states, May – august 2009. MMWR Morb Mortal Wkly Rep 2009, 58(38):1071-1074.
• [15]Rubin JL, McGarry LJ, Klugman KP, Strutton DR, Gilmore KE, Weinstein MC: Public health and economic impact of vaccination with 7-valent pneumococcal vaccine (PCV7) in the context of the annual influenza epidemic and a severe influenza pandemic. BMC Infect Dis 2010, 10:14. BioMed Central Full Text
• [16]Advisory Committee on Immunization Practices: Preventing pneumococcal disease among infants and young children: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep 2000, 49(RR-9):1-35.
• [17]Centers for Disease Control and Prevention: Active Bacterial Core Surveillance (ABCs) Report: Emerging Infections Program Network. Streptococcus pneumoniae 2006. http://www.cdc.gov/abcs/reports-findings/survreports/spneu06.html webcite Accessed December 24, 2008
• [18]Centers for Disease Control and Prevention: Active Bacterial Core Surveillance (ABCs) Report: Emerging Infections Program Network. Streptococcus pneumoniae 1998. http://www.cdc.gov/abcs/reports-findings/survreports/spneu98.html webcite Accessed December 24, 2008
• [19]Centers for Disease Control and Prevention: Progress in introduction of pneumococcal conjugate vaccine--worldwide, 2000–2008. MMWR Morb Mortal Wkly Rep 2008, 57(42):1148-1151.
• [20]Grijalva CG, Nuorti JP, Arbogast PG, Martin SW, Edwards KM, Griffin MR: Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 2007, 369(9568):1179-1186.
• [21]Centers for Disease Control and Prevention: Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for Use among children – advisory committee on immunization practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep 2010, 59(09):258-261.
• [22]Rubin JL, McGarry LJ, Strutton DR, Pelton SI, Gilmore KE, Weinstein MC: Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the united states. Vaccine 2010, 28(48):7634-7643.
• [23]Gold MR, Siegel JE, Russell LB, Weinstein MC: Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
• [24]Centers for Disease Control and Prevention: Active Bacterial Core Surveillance (ABCs) program (unpublished data, March 2009) – provided by Matt Moore. MD;
• [25]Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, Reingold A, Thomas A, Schaffner W, Craig AS, Smith PJ, Beall BW, Whitney CG, Moore MR, Active Bacterial Core Surveillance/Emerging Infections Program Network: Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010, 201(1):32-41.
• [26]Centers for Disease Control and Prevention: Active Bacterial Core Surveillance (ABCs) Report: Emerging Infections Program Network. Streptococcus pneumoniae 2007. http://www.cdc.gov/abcs/reports-findings/survreports/spneu07.html webcite Accessed December 24, 2008
• [27]U.S. Department of Health and Human Services, National Center for Health Statistics: National Ambulatory Medical Care Survey. 2006.
• [28]U.S. Department of Health and Human Services, National Center for Health Statistics: National Hospital Ambulatory Medical Care Survey. 2006.
• [29]Lieu TA, Ray GT, Black SB, Butler JC, Klein JO, Breiman RF, Miller MA, Shinefield HR: Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children. JAMA 2000, 283(11):1460-1468.
• [30]Shepard CW, Ortega-Sanchez IR, Scott RD II, Rosenstein NE, ABCs Team: Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States. Pediatrics 2005, 115(5):1220-1232. 283
• [31]Tsai CJ, Griffin MR, Nuorti JP, Grijalva CG: Changing epidemiology of pneumococcal meningitis after the introduction of pneumococcal conjugate vaccine in the United States. Clin Infect Dis 2008, 46(11):1664-1672.
• [32]Miniño AM, Heron MP, Murphy SL, Kochankek KD: Deaths: Final Data for 2004. National Vital Statistics Reports, 55(19). Hyattsville, MD: National Center for Health Statistics; 2007.
• [33]Ray GT, Whitney CG, Fireman BH, Ciuryla V, Black SB: Cost-effectiveness of pneumococcal conjugate vaccine- evidence from the first 5 years of use in the United States incorporating herd effects. Pediatr Infect Dis J 2006, 25(6):494-501.
• [34]Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, Elvin L, Ensor KM, Hackell J, Siber G, Malinoski F, Madore D, Chang I, Kohberger R, Watson W, Austrian R, Edwards K, Northern California Kaiser Permanente Vaccine Study Center Group: Efficacy, safety, and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 2000, 19(3):187-195.
• [35]Black SB, Shinefield HR, Ling S, Hansen J, Fireman B, Spring D, Noyes J, Lewis E, Ray P, Lee J, Hackell J: Effectiveness of heptavalent pneumococcal conjugate vaccine in children less than five years of age for prevention of pneumonia. Pediatr Infect Dis J 2002, 21(9):810-815.
• [36]Hansen J, Black S, Shinefield H, Cherian T, Benson J, Fireman B, Lewis E, Ray P, Lee J: Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using world health organization standardized interpretation of chest radiographs. Pediatr Infect Dis J 2006, 25(9):779-781.
• [37]Zhou F, Shefer A, Kong Y, Nuorti JP: Trends in acute otitis media-related health care utilization by privately insured young children in the United States, 1997–2004. Pediatrics 2008, 121(2):253-260.
• [38]Zhou F, Kyaw MH, Shefer A, Winston CA, Nuorti JP: Health care utilization for pneumonia in young children after routine pneumococcal conjugate vaccine use in the United States. Arch Pediatr Adolesc Med 2007, 161(12):1162-1168.
• [39]Centers for Disease Control and Prevention: Updated CDC Estimates of 2009 H1N1 Influenza Cases, Hospitalizations and Deaths in the United States, April 2009 – April 10, 2010. http://www.cdc.gov/h1n1flu/estimates_2009_h1n1.htm webcite Accessed July 14, 2010
• [40]Reed C, Angulo FJ, Swerdlow DL, Lipsitch M, Meltzer MI, Jernigan D, Finelli L: Estimates of the prevalence of pandemic (H1N1) 2009, United States, April - July 2009. Emerg Infect Dis 2009, 49(12):1811-1820.
• [41]Centers for Disease Control and Prevention: Surveillance for pediatric deaths associated with 2009 pandemic influenza a (H1N1) virus infection – united states, April-August 2009. MMWR Morb Mortal Wkly Rep 2009, 58(34):941-947.
• [42]Morgan OW, Bramley A, Fowlkes A, Freedman DS, Taylor TH, Gargiullo P, Belay B, Jain S, Cox C, Kamimoto L, Fiore A, Finelli L, Olsen SJ, Fry AM: Morbid obesity as a risk factor for hospitalization and death due to 2009 pandemic influenza a(H1N1) disease. PLoS One 2010, 5(3):e9694.
• [43]Flegal KM, Carroll MD, Ogden CL, Curtin LR: Prevalence and trends in obesity among US adults, 1999–2008. JAMA 2010, 303(3):235-241.
• [44]Ray GT, Pelton SI, Klugman KP, Strutton D, Moore MR: Cost-effectiveness of pneumococcal conjugate vaccine: an update after years of use in the United States. Vaccine 2009, 27:6483-6494.
• [45]Louie JK, Acosta M, Winter K, Jean C, Gavali S, Schechter R, Vugia D, Harriman K, Matyas B, Glaser CA, Samuel MC, Rosenberg J, Talarico J, Hatch D, California Pandemic (H1N1) Working Group: Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. JAMA 2009, 302(17):1896-1902.
• [46]Nguyen-Van-Tam JS, Openshaw PJ, Hashim A, Gadd EM, Lim WS, Semple MG, Read RC, Taylor BL, Brett SJ, McMenamin J, Enstone JE, Armstrong C, Nicholson KG, Influenza Clinical Information Network (FLU-CIN): Risk factors for hospitalisation and poor outcome with pandemic A/H1N1 influenza: United Kingdom first wave (May-September 2009). Thorax 2010, 65(7):645-651.
• [47]Fiore AE, Shay DK, Broder K, Iskander JK, Uyeki TM, Mootrey G, Bresee JS, Cox NJ, Centers for Disease Control and Prevention: Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep 2009, 58:1-52.
• [48]Melegaro A, Edmunds WJ: Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Vaccine 2004, 22(31–32):4203-4214.
• [49]Oostenbrook R, Moll H, Essink-Bot ML: The EQ-5D and the Health Utilities Index for permanent sequelae after meningitis: a head-to-head comparison. J Clin Epidemiol 2002, 55(8):791-799.
• [50]Erickson LJ, De Wals P, McMahon J, Heim S: Complications of meningococcal disease in college students. Clin Infect Dis 2001, 33(5):737-739.